SCHEMBL6285829

SCHEMBL6285829

Nc1cccc(NC(=O)Nc2ncc(Br)s2)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 10/20 0.65
DDX3X O00571 2/20 0.60
CCNE1 P24864 3/20 0.47
CDK2 P24941 3/20 0.47
CDK5 Q00535 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
CSNK2A3 Q8NEV1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285669 0.85 DYRK1A (0.56) FBP1CCNE1CDK2CDK5ALDH1A1
SCHEMBL6287753 0.84 FBP1 (0.65) FBP1ALDH1A1MEN1NPC1LMNA
SCHEMBL6283549 0.83 MAPT (0.56) FBP1CCNE1CDK2CDK5ALDH1A1
SCHEMBL4715713 0.83 CDK2 (0.63) FBP1CCNE1CDK2CDK5ALDH1A1
SCHEMBL6288099 0.82 CNR1 (0.66) DDX3XCCNE1CDK2CDK5ALDH1A1
SCHEMBL6285536 0.82 CCNE1 (0.67) FBP1DDX3XCCNE1CDK2CDK5
SCHEMBL6282772 0.81 CDK2 (0.73) FBP1DDX3XCCNE1CDK2CDK5
SCHEMBL6286205 0.81 RAB9A (0.62) ALDH1A1MEN1NPC1LMNAMAPT
SCHEMBL6278567 0.80 KMT2A (0.64) DDX3XALDH1A1MEN1NPC1LMNA
SCHEMBL6279150 0.78 TSHR (0.55) FBP1CCNE1CDK2CDK5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 FBP1 2931/4885DDX3X 4415/4885CCNE1 83/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 FBP1 2931/4885DDX3X 4415/4885CCNE1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.